Dianthus Therapeutics, Inc. revenue

Revenue history

AnnualQuarterly

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Dianthus Therapeutics, Inc.: revenue history, annual

Fiscal year	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	0	0	0	0	2,826	6,235	2,036
Growth on the year before	—	—	—	—	—	+120.6%	−67.3%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Dianthus Therapeutics, Inc.	$2.0m	-67.3%	—
Korsana Biosciences, Inc.	$1.9m	-12.6%	—
Seres Therapeutics, Inc.	$1.9m	100.0%	-75.6%
Collplant Biotechnologies Ltd	$2.4m	360.4%	—
Korro Bio, Inc.	$2.4m	-62.1%	-53.7%
Vistagen Therapeutics, Inc.	$2.5m	287.3%	—

Compare with peers

• Korsana Biosciences, Inc. revenue
• Seres Therapeutics, Inc. revenue
• Collplant Biotechnologies Ltd revenue
• Korro Bio, Inc. revenue
• Vistagen Therapeutics, Inc. revenue

Head to head: DNTH vs KRSADNTH vs MCRBCLGN vs DNTH

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Dianthus Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Dianthus Therapeutics, Inc.